These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36789801)

  • 1. Safety of stimulant medications for attention deficit hyperactivity disorder in paediatric congenital heart disease.
    Chung LM; Hariharan G; Varma S
    J Paediatr Child Health; 2023 Mar; 59(3):580-588. PubMed ID: 36789801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.
    Batra AS; Alexander ME; Silka MJ
    Pediatr Cardiol; 2012 Mar; 33(3):394-401. PubMed ID: 22298228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S
    Curr Opin Pediatr; 2016 Oct; 28(5):607-12. PubMed ID: 27261563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulant Medication Treatment in Children with Congenital Heart Disease and Attention-Deficit/Hyperactivity Disorder: Cardiovascular Outcomes.
    Trairatvorakul P; Meinzen-Derr J; Heydarian H; Mason K; Anixt JS
    J Dev Behav Pediatr; 2023 May; 44(4):e247-e254. PubMed ID: 37081695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Cerrillo-Urbina AJ; García-Hermoso A; Pardo-Guijarro MJ; Sánchez-López M; Santos-Gómez JL; Martínez-Vizcaíno V
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):494-507. PubMed ID: 29897263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?
    Rohatgi RK; Bos JM; Ackerman MJ
    Heart Rhythm; 2015 Aug; 12(8):1807-12. PubMed ID: 25956966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective.
    Shahani SA; Evans WN; Mayman GA; Thomas VC
    Pediatr Cardiol; 2014 Mar; 35(3):485-9. PubMed ID: 24141829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Central Nervous System Stimulant Medication Use on Growth in Pediatric Populations with Attention-Deficit/Hyperactivity Disorder: A Review.
    Troksa K; Kovacich N; Moro M; Chavez B
    Pharmacotherapy; 2019 Jun; 39(6):665-676. PubMed ID: 30368860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.
    Blader JC; Pliszka SR; Kafantaris V; Foley CA; Carlson GA; Crowell JA; Bailey BY; Sauder C; Daviss WB; Sinha C; Matthews TL; Margulies DM
    J Am Acad Child Adolesc Psychiatry; 2021 Feb; 60(2):236-251. PubMed ID: 32007604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Olfson M; Huang C; Gerhard T; Winterstein AG; Crystal S; Allison PD; Marcus SC
    J Am Acad Child Adolesc Psychiatry; 2012 Feb; 51(2):147-56. PubMed ID: 22265361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL; Kuchibhatla A
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexmethylphenidate for attention deficit hyperactivity disorder.
    Coury D
    Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of attention deficit/hyperactivity disorder in children with CHD.
    Pierick AR; Lynn M; McCracken CM; Oster ME; Iannucci GJ
    Cardiol Young; 2021 Jun; 31(6):969-972. PubMed ID: 33517944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review.
    Cook J; Lloyd-Jones M; Arunogiri S; Ogden E; Bonomo Y
    Aust N Z J Psychiatry; 2017 Sep; 51(9):876-885. PubMed ID: 28639480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
    Eaton C; Yong K; Walter V; Mbizvo GK; Rhodes S; Chin RF
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013136. PubMed ID: 35844168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.